For more information, visit: www.miltenyibiotec.com/DE-en/... The recent successes of chimeric antigen receptor (CAR) T cell therapy in hematologic malignancies have led to tremendous interest in the immunotherapeutic field, and the potential of genetically modified T cells now expands into solid tumors and infectious diseases. However, current manufacturing processes for CAR T cells are complex and labor-intensive.
In this two-part webinar you will learn more about the new T Cell Transduction - Large Scale (TCT-LS) process for the CliniMACS Prodigy® Platform. We share process details and differentiators, along with limitations and how to choose the right process type for your requirements. Furthermore, we will walk you through recent data on TCR-modified T cell manufacturing for AML treatment, and how the overall process was shortened to only 8 days.
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries - all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.